Skip to main content
Caplight Logo









Broadwing Bio

Broadwing Bio

Private
San Francisco, CaliforniaHealthcare & Life Scienceshttps://broadwing.bio/

Last Round

Convertible Debt

Feb 2, 2024

Total Funding Raised

$9.9M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Broadwing Bio is a biotechnology company that develops targeted antibody therapies for the treatment of ophthalmic diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share

AI Layer

Non-AI

Keywords

biotechnologydrug discoveryantibody therapeuticsophthalmologybiotechgeographic atrophyglaucoma treatmenttherapeutic pipelinedrug developmentbiologicsout-licensingfunctional genomicspreclinical developmentbiotech startup

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Broadwing Bio Comparables

Compare Broadwing Bio with similar companies based on industry and business-model similarity.

Broadwing Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Galimedix Therapeutics
79%
Annexon Biosciences
77%
ONL Therapeutics
74%

Broadwing Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Convertible DebtFeb 2, 2024
Corporate FundingDec 7, 2020

Broadwing Bio Investors

Notable investors and investment history

Broadwing Bio investors
InvestorRounds
Echo Investment CapitalConvertible Debt

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 24, 2026

    Monthly visitors increased 238% MoM.

  • Feb 2, 2024

    $10M raised from Echo Investment Capital and others.

Broadwing Bio Filings

Explore SEC and related filing metadata, where available.

Broadwing Bio filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Broadwing Bio's valuation, stock price, and market status.

Is Broadwing Bio a public or private company?

Broadwing Bio is a private company.

What is the current stock price of Broadwing Bio?

Broadwing Bio is a private company with no public stock price. No recent secondary market data is available.

How much is Broadwing Bio worth (valuation)?

Valuation information for Broadwing Bio is not publicly available.

Can I buy Broadwing Bio stock?

Broadwing Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Broadwing Bio's last funding round?

Broadwing Bio's most recent funding round was Convertible Debt on February 2, 2024.

Who are the main investors in Broadwing Bio?

Key investors in Broadwing Bio include Echo Investment Capital.

Will Broadwing Bio IPO soon?

No public IPO plans have been announced for Broadwing Bio.

How can I track Broadwing Bio secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Broadwing Bio's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSan Francisco, California
Employee Range4
Year Founded2020
Last FundingFeb 2, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?